BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 11880117)

  • 1. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
    Kawano M; Kuroda Y; Terao M; Yaginuma T; Kawakami M; Kanazawa Y
    Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
    Rustemeijer C; Schouten JA; Voerman HJ; Hensgens HE; Donker AJ; Heine RJ
    Diabetes Metab Res Rev; 2000; 16(2):82-7. PubMed ID: 10751747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia.
    Stewart MW; Dyer RG; Alberti KG; Laker MF
    Diabet Med; 1995 Mar; 12(3):250-7. PubMed ID: 7758262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
    Nakamura T; Ushiyama C; Osada S; Inoue T; Shimada N; Koide H
    J Diabetes Complications; 2003; 17(6):349-54. PubMed ID: 14583180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
    Nakandakare E; Garcia RC; Rocha JC; Sperotto G; Oliveira HC; Quintão EC
    Atherosclerosis; 1990 Dec; 85(2-3):211-7. PubMed ID: 2102085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    Ruotolo G; Ericsson CG; Tettamanti C; Karpe F; Grip L; Svane B; Nilsson J; de Faire U; Hamsten A
    J Am Coll Cardiol; 1998 Nov; 32(6):1648-56. PubMed ID: 9822092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
    Nakamura T; Matsuda T; Suzuki Y; Ueda Y; Koide H
    ASAIO J; 2003; 49(4):430-4. PubMed ID: 12918586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
    Jeck T; Riesen WF; Keller U
    Diabet Med; 1997 Jul; 14(7):564-70. PubMed ID: 9223394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
    Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effect of bezafibrate on improvement of atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance.
    Hayashi K; Kurushima H; Kuga Y; Shingu T; Tanaka K; Yasunobu Y; Nomura K; Ohtani H; Hiraga T; Toyota Y; Katano T; Sakai-Ohta K; Kajiyama G
    Cardiovasc Drugs Ther; 1998 Mar; 12(1):3-12. PubMed ID: 9607127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments.
    Lane DM; Alaupovic P; Knight-Gibson C; Dudley VS; Laughlin LO
    Am J Cardiol; 1995 Jun; 75(16):1124-9. PubMed ID: 7762498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single LDL apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects.
    Kobayashi J; Katsube S; Shimoda M; Furuhashi K; Kitano S; Masuda M; Maruyama T; Shinomiya M
    Clin Chim Acta; 2002 Jul; 321(1-2):107-12. PubMed ID: 12031599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration.
    Totsuka M; Miyashita Y; Ito Y; Watanabe H; Murano T; Shirai K
    Atherosclerosis; 2000 Nov; 153(1):175-9. PubMed ID: 11058713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy.
    Arai T; Yamashita S; Yamane M; Manabe N; Matsuzaki T; Kiriyama K; Kanayama Y; Himeno S; Matsuzawa Y
    Atherosclerosis; 2003 Aug; 169(2):293-9. PubMed ID: 12921981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bezafibrate reduces blood glucose in type 2 diabetes mellitus.
    Ogawa S; Takeuchi K; Sugimura K; Fukuda M; Lee R; Ito S; Sato T
    Metabolism; 2000 Mar; 49(3):331-4. PubMed ID: 10726910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
    Lappegård KT; Enebakk T; Thunhaug H; Hovland A
    Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
    Triolo M; Annema W; de Boer JF; Tietge UJ; Dullaart RP
    Eur J Clin Invest; 2014; 44(3):240-8. PubMed ID: 24325778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG; Lang PD
    Atherosclerosis; 1978 Dec; 31(4):429-33. PubMed ID: 215175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive lipid-lowering strategy in patients with diabetes mellitus.
    Kanters SD; Algra A; de Bruint TW; Erkelens DW; Banga JD
    Diabet Med; 1999 Jun; 16(6):500-8. PubMed ID: 10391399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.